The Advisory Committee on Immunization Practices (ACIP), which assists the U.S. Centers for Disease Control and Prevention (CDC), recently recommended that people at higher risk receive the serogroup B meningococcal vaccine.
The ACIP advised that anyone 10 years and older should receive the serogroup B meningococcal vaccine if they have anatomic or functional asplenia, live in an area with an outbreak of the illness, experience recurring complement component deficiencies, or regularly are exposed to Neisseria meningitides isolates.
“We are encouraged by this initial ACIP recommendation,” Dr. Laura York, global medical lead for meningococcal vaccines at Pfizer Vaccines, said. “However, we believe public health would be best served by broader routine recommendations for adolescents and young adults who are currently only protected against serogroups A, C, W and Y. We look forward to continued dialogue with the CDC on the most appropriate vaccination strategies toward prevention of serogroup B meningococcal disease in adolescents and young adults.”
The U.S. Food and Drug Administration recently gave Pfizer’s TRUMENBA Meningococcal Group B Vaccine an accelerated path to active immunization.
“While uncommon, meningitis B cases continue to be reported on college campuses,” Susan Silbermann, president of Pfizer Vaccines, said. “We believe a recommendation for adolescents and young adults to be vaccinated against serogroup B meningococcal disease can't come early enough. Everyone’s goal should be to allow enough time for students to start their vaccination before they return to school next fall.”